Medicamen Biotech Ltd (MEDICAMEQ) Share Price & Fundamentals

What we do

Medicamen Biotech Ltd is a research-led pharmaceutical company manufacturing and marketing finished dosage formulations in India and over 35 countries, specializing in oncology and various therapeutic categories.

Founded in

1,993

Market share

Among leading oncology firms in India with robust presence in domestic and international markets including Africa and Australia.

Problem solved

Provides affordable, high-quality medicines across multiple therapeutic areas addressing healthcare needs domestically and globally.

Top clients or who we serve

Serves domestic Indian market (B2B and B2C) and exports to African, CIS, and Australian pharmaceutical markets (B2B).

Key management

Chief Executive Officer: Mr. Rajesh Madan; CFO: Mr. Chandan Kumar; Company Secretary: Ms. Parul Choudhary.

Our journey and innovations

Founded in 1993; listed in 1995; expanded manufacturing with CGMP and EU GMP approvals; acquired Australian subsidiary; entered oncology market in 2022.

Where we operate

Operates mainly in India with exports to over 35 countries including Africa, CIS, and Australia.

Top products or what we offer

Offers finished dosage forms in oncology, Pain Management, Cough & Cold, Cardiovascular, CNS, Anti-Diabetic, GI, and Anti-Allergic segments.

Top brands

-

Raw materials needed

Pharmaceutical ingredients for tablets, capsules, oral liquids, ointments, and creams.

Raw materials supplier

-

Recurring vs cyclical contribution

Revenue mostly recurring from steady pharmaceutical product sales domestically and internationally.

Our industry position

Strong player in Indian oncology segment; supplier to African and CIS markets; EU GMP certified facility enhances competitive edge.

Financial highlights

FY25 consolidated revenue ₹162.55 Cr; net profit ₹7.11 Cr; slight decline vs prior year due to market conditions.

Geographical revenue split

Revenue primarily from India and exports to Africa, CIS, and Australia; exact split not specified.

Order book

-

Whats driving growth

Growth driven by oncology product launches, international market expansion, capacity upgrades, and government contract fulfilments.

Our future plans

Expanding oncology portfolio, strengthening exports, and enhancing manufacturing capabilities aligned with global standards.

Our green promise

-

Our people and values

Cultivates ethical culture with zero tolerance for corruption; embraces diversity and upholds robust governance practices.

Key challenges ahead

Market competition, regulatory compliance, and managing global economic impacts on pharmaceutical demand.

Interesting facts

Bhiwadi facility achieved EU GMP approval (2025); substantial exports to African countries and Australia.

Risks and strategy

Mitigates risks via strong governance, compliance, diversified markets, and continuous product innovation.